Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis

Recruiting N/A Interventional Study
Psychosis; Schizophrenia-Like Healthy Controls
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
15 – 35
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
300 (estimated)
Sponsor
Beth Israel Deaconess Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study, "Psychobiological Follow-up Study of Transition from Prodrome to Early Psychosis", will be conducted in collaboration with the Shanghai Mental Health Center (SMHC) and several data processing sites in the United States. The current study builds on findings from the investigator's previous work that identified several biomarkers in participants at clinical high risk (CHR) for psychosis …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Clinical High Risk (CHR): 1. Male or female between 15 and 35 years old. 2. Can understand and sign an informed consent (or assent for minors) document. 3. Must meet the substance use criteria: 1. No Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM…
Contacts

William S Stone, Ph.D.

5087402050

wstone@bidmc.harvard.edu

CONTACT

Margaret A Niznikiewicz, Ph.D.

6176534627

margaret_niznikiewicz@hms.harvard.edu

CONTACT